Effect of Kinesiotaping Augmented By Resistive Exercise on Fatigue, Physical Strength, Quality of Life in Breast Cancer Survivors

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05726643
Collaborator
(none)
40
1
2
3.9
10.1

Study Details

Study Description

Brief Summary

The purpose of the study will be to investigate the effect of kinesotaping augmented by resistive exercise on fatigue, muscle strength, and QoL in breast cancer survivors.

Condition or Disease Intervention/Treatment Phase
  • Other: resistive training
  • Other: kinesiotaping
N/A

Detailed Description

The present study will provide an evidence base to women's health care providers about the effect of strength training augmented by kinesotaping on fatigue, QoL and muscle strength in breast cancer women compared to strength training alone

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Effect of Kinesiotaping Augmented By Resistive Exercise on Fatigue, Physical Strength, Quality of Life in Breast Cancer Survivors
Anticipated Study Start Date :
Feb 20, 2023
Anticipated Primary Completion Date :
May 20, 2023
Anticipated Study Completion Date :
Jun 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: resistive training group

consists of 20 patients who will receive resistive training for 2times per week for 12 weeks

Other: resistive training
5 minutes warming up exercise for various parts of the body as moderately energetic walking. 5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times. 10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times.

Experimental: kinesotaping group

consists of 20 patients who will receive resistive training program augmented by kinesotaping, 2 times /week for 12 weeks.

Other: resistive training
5 minutes warming up exercise for various parts of the body as moderately energetic walking. 5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times. 10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times.

Other: kinesiotaping
Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.

Outcome Measures

Primary Outcome Measures

  1. Assessing the change in fatigue [at baseline and after 12 weeks of intervention]

    The Fatigue Severity Scale is a 14-item will be used to measure the severity, frequency and diurnal variation of fatigue, as well as its perceived interference with quality of life.

  2. Assessing the change in quality of life [at baseline and after 12 weeks of intervention]

    By using 36-Item Short Form (SF-36) health survey will be used to assess QoL. The SF-36 questionnaire includes eight multiple-item subscales that evaluate physical function, social functioning, role limitations due to physical problems and role limitations due to emotional problems, mental health, vitality, pain and general health perception. Total score on each SF-36 subscale ranges between 0 and 100. Greater score indicates better QoL

  3. Assessing the change in muscle strength [at baseline and after 12 weeks of intervention]

    Muscle strength will be assessed using dynamometer at starting and after 12 weeks of the treatment course.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patient's age will range from 40- 55 years.

  • Their body mass index (BMI) will be from 25 to 29,9 Kg/m2.

  • They suffer from breast cancer.

  • They will receive chemotherapy within previous 3 months.

  • They complain from fatigue, deterioration in their daily living activity (ADL) and feeling of weakness in their muscles.

Exclusion Criteria:
  • Respiratory or heart problems affecting mobility

  • Marked skeletal deformity.

  • Visual system affection.

  • Cognition problems.

  • Previous surgeries at their back and/or lower limbs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Outpatient clinic faculty of physica therapy cairo university Dokki Egypt

Sponsors and Collaborators

  • Cairo University

Investigators

  • Principal Investigator: Alaa Negm, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alaa Mos'ad Ebrahim Rmdan, Principal Investigator, Cairo University
ClinicalTrials.gov Identifier:
NCT05726643
Other Study ID Numbers:
  • Alaa_Negm_MSc_2023
First Posted:
Feb 14, 2023
Last Update Posted:
Feb 14, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 14, 2023